Senses Disorder TRIZ Cases

Modifying bumetanide substituents reduces side effects while maintaining therapeutic efficacy for addictive disorders.

A glycine compound inhibits VAP-1 enzyme activity through competitive binding.

Amido-thiophene compounds inhibit 11β-HSD1, reducing glucocorticoid activity and improving insulin sensitivity for metabolic syndrome treatment.

Replacing Tween-80 with chitosan oligosaccharide prevents degradation of deproteinized calf blood extract, ensuring clinical stability.

Entacapone derivatives inhibit the FTO enzyme, reducing retinal blood vessel diameter and improving histopathology without anti-Parkinson's agents.

Aniline-substituted diarylureas inhibit p38 MAP kinase, Syk, and Src family kinases to treat inflammatory diseases while minimizing toxicity.

L-4-chlorokynurenine converts to 7-chlorokynurenic acid in the brain, resolving blood-brain barrier penetration limits.

A multi-component ophthalmic formulation merges alpha 2 adrenergic agonists with corticosteroids to enhance tear production.

A hyaluronic acid and oligosaccharide composition forms a stable film on the ocular surface to provide lubrication.

Mesenchymal stem cells reduce hyaluronic acid and adipogenesis in orbital fibroblasts, addressing side effects of steroid treatments.

A freeze-dried silk fibroin powder maintains molecular structure and enables long-term storage.

Substituted isoindolinones modulate protein activity to reduce toxicity in healthy cells during cancer treatment.

A pharmaceutical composition combining citicoline and homotaurine enhances cholinergic transmission to support cognitive function.

Topical cannabinoid and modulator composition reduces ocular inflammation without steroid side effects.

Cuscuta japonica extract composition inhibits noise-induced hearing threshold shifts and protects hair cells from acoustic trauma damage.

Multi-target inhibition of IGFBP2, MERTK, and PITPNC1 prevents metastasis where VEGF therapy fails.

An in situ crosslinked hydrogel delivers drugs through a small gauge needle, reducing injection frequency and side effects.

Macrolides induce nonsense mutation read-through to restore full-length proteins, avoiding the dose-limiting toxicity of aminoglycosides.

Humanized antibodies bind beta-amyloid epitopes, inhibiting aggregation and reducing ocular pressure.

Reverse amide compounds target HDAC6 active sites to resolve selectivity issues in broad-spectrum inhibitors.

Novel substituted aromatic compounds treat blood and renal disorders by stimulating hematopoiesis while reducing oxidative stress and toxicity.

Imidazole derivatives inhibit GDF-8 activity to increase muscle and bone mass despite limited disease cure rates.

Nucleic acid ligands bind platelet glycoprotein VI to inhibit aggregation, enabling reversible control over therapeutic efficacy.

Fused ring system improves metabolic stability and half-life to treat sleep disorders.

Selective 6-phenyl-1H-indazole derivatives inhibit Janus kinases locally in lungs while minimizing systemic side effects from broad-spectrum inhibition.

Low-concentration benzalkonium chloride in aqueous bromfenac solutions ensures preservative efficacy while minimizing corneal side effects.

Tripeptide compounds with cationic structures treat sinusitis, pneumonia, or otitis without identifying the specific causative agent.

Tolbutamide modulates ion channels to boost aqueous humor flow, reducing intraocular pressure while improving nutrient supply.

Formula I compounds modulate P2X7 receptor activity to treat inflammatory and neurological disorders.

Segmenting a bi-layer tablet resolves the contradiction between rapid onset and sustained action, maintaining near-normal blood glucose in Type 2 diabetes.

Surfactants and terpenes permeate the tympanic membrane to deliver antibiotics directly to the middle ear, bypassing gastrointestinal side effects.

Segmented AAV delivery enables preliminary CRISPR-Cas9 editing of RPE65 mutations, providing durable therapeutic correction beyond vector clearance.

Lipid binding protein complexes solubilize ocular lipid deposits to treat LCAT deficiency and slow disease progression.

Synergistic sulfated polysaccharide and steroid compositions deliver potent anti-inflammatory activity through combined immunomodulatory mechanisms.

EDDS enhancer accelerates collagen crosslinking in ophthalmic preparations, resolving oxygen depletion bottlenecks.

PCA-PVA-PEG graft copolymers solubilize hydrophobic drugs through micelle formation, maintaining preservative efficacy while reducing formulation complexity.

Retinal-specific promoters drive CRX protein expression via AAV vectors, rescuing Rhodopsin and Opsin levels to treat autosomal dominant retinopathies.

Retinal pigment epithelial stem cells replace damaged retinal tissue to restore vision, bypassing immunosuppressive drug side effects and permanent cell loss.

Tetrahydro-pyrimidoazepine derivatives enhance TRPV1 modulating activity and pharmaceutical properties, addressing insufficient potency of existing modulators.

Small molecule triazine derivatives overcome blood-brain barrier limitations and improve pharmacokinetic properties while maintaining high potency.

Amidopyridinol derivatives inhibit angiogenic growth and cancer metastasis through targeted molecular binding.

Anti-CGRP antibodies bind CGRP receptors to prevent light aversion, avoiding adverse side effects from traditional non-specific treatments.

Humanized CD37 binding molecules reduce B-cell populations with enhanced tissue penetration and specificity.

Cell suspension from 20-22 week gestation tissue resolves low engraftment rates in lung regeneration therapies.

Optimized reagent ratios and thermal conditions in the memantine synthesis process eliminate halogenated solvents and reduce chemical waste generation.